ライフサイエンスコーパス: angiotensin receptor blocker

1 n either stand-alone neprilysin inhibitor or angiotensin receptor blocker.

2 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.

3 f angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

4 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

5 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

6 c agent that combines a NEP inhibitor and an angiotensin receptor blocker.

7 ngiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker.

8 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

9 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

10 zyme, and synthesis of its inhibitors and of angiotensin receptor blockers.

11 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

12 angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers.

13 of the next generation of beta-blockers and angiotensin receptor blockers.

14 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

15 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

16 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

17 angiotensin converting-enzyme inhibitors and angiotensin receptor blockers.

18 rt and compare to previous trials evaluating angiotensin receptor blockers.

19 .87 per 100 person-years for those receiving angiotensin receptor blockers.

20 .31; 95% CI, 1.22-1.40) than those receiving angiotensin receptor blockers.

21 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

22 and -3.07 mm Hg (95% CI, -4.99 to -1.44) for angiotensin receptor blockers.

23 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

24 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.

25 angiotensin-converting-enzyme inhibitors, or angiotensin-receptor blockers.

26 is of unproven value, even beta-blockers and angiotensin-receptor blockers.

27 (ACE) inhibitors (1.08, 1.02-1.15, p=0.008), angiotensin-receptor blockers (1.16, 1.07-1.25, p=0.0002

28 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (18.2% vs 16.9%, p = 1.000

29 e was low (beta blocker 45.9%, ACE inhibitor/angiotensin receptor blocker 31.6%, ARNI 19.0%) and for

30 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (66% versus 68%; P=0.04) a

31 ACE inhibitors/angiotensin receptor blockers (ACE-I/ARB) may counteract

32 and angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) in acute myocar

33 iotensin-converting enzyme inhibitors and/or angiotensin receptor blockers achieves only partial reno

34 An angiotensin receptor blocker added to an ACE inhibitor m

35 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers after SAVR for severe AS b

36 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers after surgical aortic valv

37 When given with an angiotensin receptor blocker, aliskiren produces signifi

38 ic shock, and mortality than those receiving angiotensin receptor blockers (all p < 0.001).

39 re angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, alpha-blockers, beta-bloc

40 ngiotensin-converting enzyme inhibitor or an angiotensin receptor blocker and appropriate limitation

41 : high dose, 0.55; low dose, 0.72; both ACEi/angiotensin receptor blocker and beta-blocker: high dose

42 We hypothesized that angiotensin receptor blocker and neprilysin inhibitor, s

43 ate, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and oral anti-diabetic agen

44 Telmisartan, an angiotensin receptor blocker and partial PPAR-gamma agon

45 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82% were receiving bet

46 expression is ameliorated by antiproteinuric angiotensin receptor blockers and angiotensin-converting

47 ith angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers and an o

48 use angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers compared

49 Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers were pre

50 edications include calcium channel blockers, angiotensin receptor blockers and converting enzyme inhi

51 For patients with persistent symptoms, angiotensin-receptor blockers and aldosterone antagonist

52 (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and statins), and adverse

53 (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and statins), and adverse

54 angiotensin converting enzyme inhibitor, and angiotensin receptor blocker), and N-terminal probrain n

55 f an angiotensin converting enzyme inhibitor/angiotensin receptor blocker, and hydrochlorothiazide 12

56 osemide, diltiazem, aspirin, simvastatin, an angiotensin receptor blocker, and insulin.

57 We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antiox

58 ing angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 4.5 million not recei

59 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aldosterone antagonis

60 aneurysmal disease, including beta-blockers, angiotensin receptor blockers, and angiotensin-convertin

61 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and beta-blockers, respec

62 th angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium antagonists y

63 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and dietary protein restr

64 s, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers, and diuretics.

65 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and more sunscreen use in

66 s, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other agents affect c

67 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and P2Y12 antagonists) re

68 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins (combination

69 rs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins after acute m

70 rs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins reduces cardi

71 n, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and beta-adrenergic block

72 irm the beneficial effect of ACE-inhibitors, angiotensin-receptor blockers, and diuretics and/or beta

73 tency is approximately equivalent to that of angiotensin receptor blockers, angiotensin-converting en

74 with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-nepril

75 e of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-nepril

76 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, antiplatelet drugs, beta-

77 Pre-hospital use vs. non-use of angiotensin receptor blockers (aOR 2.02, CI 1.03-3.96) a

78 Angiotensin receptor blockers appear to be as effective

79 1.73 m(-2)), greater renal vasodilation with angiotensin receptor blockers (approximately 145 mL x mi

80 otensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) affected the results.

81 ]: 1.04 to 1.10) and discharge ACE inhibitor/angiotensin receptor blocker (ARB) in LV dysfunction (64

82 tensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences disease ou

83 comparable antihypertensive activity to the angiotensin receptor blocker (ARB) losartan.

84 tensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic ev

85 The combination of a diuretic and an angiotensin receptor blocker (ARB) or angiotensin-conver

86 ology study uses claims data to characterize angiotensin receptor blocker (ARB) prescription trends t

87 ensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) should be used for se

88 nical trials (RCT), ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy have emerged

89 ed in increased cancer risk, with a focus on angiotensin receptor blocker (ARB) therapy, as recent pu

90 1) but had similar rates of ACE inhibitor or angiotensin receptor blocker (ARB) use (85.7% black vs 8

91 giotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and mortality in

92 otensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) use, ESA use, dialysi

93 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are generally well t

94 nsin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) doses on outcomes in

95 The advent of orally active angiotensin receptor blockers (ARB) increases the number

96 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) initiated after myoc

97 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) were associated with

98 otensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-blockers (BB),

99 At last follow-up, with the use of angiotensin receptor blockers (ARB), the Up/c declined t

100 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).

101 tly less likely after dual treatment with an angiotensin-receptor blocker (ARB) and an angiotensin-co

102 To determine whether the angiotensin-receptor blocker (ARB) candesartan decreases

103 otensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) for patients with lef

104 iotensin-converting enzyme inhibition and/or angiotensin-receptor blocker (ARB) therapy (group 1) wer

105 nsin-converting-enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARB).

106 irectly inhibit the angiotensin II receptor (angiotensin receptor blocker [ARB]) has provided clinici

107 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and beta blockers.

108 nsin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and sodium-glucose

109 nin angiotensin system pathways suggest that angiotensin receptor blockers (ARBs) are ideal drugs to

110 nsin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widely prescrib

111 sin-converting-enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) both increased sign

112 Angiotensin receptor blockers (ARBs) convert myofibrobla

113 The use of angiotensin receptor blockers (ARBs) correlates with red

114 ertensive patients (n = 469), patients using angiotensin receptor blockers (ARBs) did not show a decl

115 PURPOSE OF REVIEW: As their introduction, angiotensin receptor blockers (ARBs) have been widely pr

116 ensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventr

117 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in patients with ty

118 ensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in preventing the n

119 several years have examined indications for angiotensin receptor blockers (ARBs) in the treatment of

120 Because angiotensin receptor blockers (ARBs) lack a direct effec

121 has revealed that ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be beneficial i

122 Preclinical data suggest that angiotensin receptor blockers (ARBs) may have similar st

123 sin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) may increase the ri

124 otensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) may make patients m

125 in-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) on the composite of

126 iotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (

127 iotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, and

128 otensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), beta-blockers, and

129 target the renin angiotensin system, such as angiotensin receptor blockers (ARBs), have been associat

130 in-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs), may be associated

131 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).

132 lyses assessed therapeutic substitution with angiotensin receptor blockers (ARBs).

133 A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-con

134 Angiotensin-receptor blockers (ARBs) are a widely used d

135 Angiotensin-receptor blockers (ARBs) are effective treat

136 ensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinur

137 sin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in coronavirus dise

138 ensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical co

139 The role of angiotensin-receptor blockers (ARBs) in treating patient

140 ensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) reduce cardiovascul

141 tensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) who filled brand-na

142 ensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), 3-hydroxy-3-methyl

143 tensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and beta blockers

144 iotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), beta blockers, and

145 allergic myocardial infarction, anaphylaxis, angiotensin-receptor blockers (ARBs), beta-adrenergic bl

146 recent analysis showing increased risk with angiotensin-receptor blockers (ARBs).

147 tensin-converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], and beta-blockers

148 nsin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and cilostazol) an

149 used in the clinic AT(1)R antagonist drugs (angiotensin receptor blockers, ARBs, or sartans) at prev

150 Angiotensin receptor blockers are renoprotective in hype

151 angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with gr

152 ker 31.6%, ARNI 19.0%) and for ACE inhibitor/angiotensin receptor blocker/ARNI, decreased over time.

153 angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker as foundational therapy, wi

154 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker at discharge, have little r

155 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers at admission), beta-blocke

156 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers at discharge decreased in

157 nsin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally t

158 g angiotensin converting enzyme inhibitor or angiotensin receptor blocker background therapy.

159 sing angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (beta=0.36, P<0.001; CI: 0.

160 tensin-converting enzyme inhibitor (ACEi, or angiotensin receptor blocker), beta-blocker, or both dru

161 for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralo

162 ent (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralo

163 n patients receiving higher doses of ACEi or angiotensin receptor blocker, beta-blocker, or both (haz

164 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta blockers, calcium ch

165 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, aldosteron

166 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, aldosteron

167 Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and aldost

168 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and dual a

169 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and dual a

170 sed angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and statin

171 (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, spironolac

172 ing angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, beta-blockers, and devic

173 of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta blockers, calcium-ch

174 ng angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, and minera

175 s (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, calcium ch

176 ween previous treatment with ACE inhibitors, angiotensin-receptor blockers, beta-blockers, calcium-ch

177 an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker, o

178 ., angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers,

179 ) administration of ultrahigh dosages of the angiotensin receptor blocker candesartan on the progress

180 clinical trial, comparing the effects of the angiotensin receptor blocker candesartan with placebo in

181 The angiotensin receptor blocker component of LCZ696, valsar

182 We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and

183 We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in s

184 and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers decreased from 89%, 84.9%,

185 s, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium c

186 f angiotensin-convering enzyme inhibitors or angiotensin receptor blockers during the study and a his

187 cardiovascular examples, such as the use of angiotensin receptor blockers for chronic heart failure,

188 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for more than 90 days betw

189 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for secondary prevention a

190 (3) angiotensin-converting enzyme inhibitor/angiotensin receptor blockers for systolic dysfunction,

191 he therapeutic benefits of beta-blockers and angiotensin receptor blockers given the emerging concept

192 sin Receptor-Neprilysin Inhibitor] with ARB [Angiotensin Receptor Blocker] Global Outcomes in HFpEF),

193 angiotensin-converting enzyme inhibitor and angiotensin receptor blocker groups resulted in two simi

194 ted, whereas acute HF and patients receiving angiotensin receptor blocker had higher plasma Ang II wi

195 been demonstrated that Valsartan (Val) as an angiotensin receptor blocker has renoprotective effects,

196 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers has become a crucial eleme

197 Specific benefits beyond those of other angiotensin receptor blockers have been claimed for tele

198 nd clinical data support the hypothesis that angiotensin receptor blockers have beneficial effects on

199 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have demonstrated benefici

200 Angiotensin receptor blockers have not been shown to be

201 vitro, specific actions not shared by other angiotensin receptor blockers have not yet been convinci

202 rd ratio for eplerenone versus placebo, ACEi/angiotensin receptor blocker: high dose, 0.67; low dose,

203 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (HR, 0.90; 95% CI, 0.79-1.

204 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ie, renin-angiotensin sys

205 (angiotensin-converting enzyme) inhibitor or angiotensin receptor blocker if left ventricular ejectio

206 Thiazide diuretics, ACE-inhibitors or angiotensin receptor blockers if ACE-inhibitor-intoleran

207 uggest that aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure

208 r angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in eligible patients.

209 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in persons with CKD to impr

210 Six previous trials of angiotensin receptor blockers in HCM enrolled a median o

211 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19.

212 rdial infarction patients suggest a role for angiotensin receptor blockers in patients with heart fai

213 ngiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with heart fai

214 Available data support the use of angiotensin receptor blockers in persons with type 2 dia

215 w data exist concerning the effectiveness of angiotensin receptor blockers in this population.

216 definitive studies have examined the use of angiotensin-receptor blockers in patients with type 2 di

217 in-converting enzyme inhibitor) or losartan (angiotensin-receptor blocker) in FSGS mice stimulated th

218 ngiotensin-converting enzyme inhibitors, and angiotensin receptor blockers increased by 23%, 57%, 31%

219 ensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers increases the likelihood o

220 Treatment for 4 weeks with the angiotensin receptor blocker irbesartan, but not with th

221 transinhibitory effect of beta-blockers and angiotensin receptor blockers is through receptor-G prot

222 Providing the anti-fibrotic angiotensin receptor blocker losartan to mice in drinkin

223 The angiotensin receptor blocker losartan was given to half

224 st orally active direct renin inhibitor, the angiotensin-receptor blocker losartan, and their combina

225 itors (captopril, fosinopril, ramipril), and angiotensin receptor blockers (losartan, candesartan).

226 w warranted to establish the extent to which angiotensin receptor blockers may provide antiinflammato

227 ean BP reduction 12.9/7.7 mm Hg; p < 0.003), angiotensin-receptor blockers (mean BP reduction 13.3/7.

228 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartil

229 Combined angiotensin receptor blocker neprilysin inhibitors (ARNI

230 Angiotensin receptor blocker-neprilysin inhibitor (ARNi)

231 A combination of angiotensin receptor blocker/neprilysin inhibitors (ARNi

232 ng the effects of aliskiren combined with an angiotensin receptor blocker on intermediate markers of

233 etermine the effects of pretreatment with an angiotensin receptor blocker on left ventricular (LV) fu

234 f the study was to evaluate the effect of an angiotensin receptor blocker on left ventricular (LV) st

235 giotensin receptor neprilysin inhibitor with angiotensin receptor blocker on Management Of heart fail

236 unity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone level

237 and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on outcome in patients wit

238 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk and outcomes o

239 ting the renoprotective benefit of adding an angiotensin receptor blocker or a mineralocorticoid rece

240 e of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or beta-blocker and 60- to

241 he renin-angiotensin-aldosterone system with angiotensin receptor blockers or angiotensin-converting

242 DMT (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, or beta-blocker) at baseli

243 le angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or both.

244 of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or sacubitril-valsartan.

245 of angiotensin converting enzyme inhibitors/angiotensin receptor blockers (P = 0.02).

246 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (p = 0.029), higher biliru

247 ile lower ATP was associated with the use of angiotensin receptor blockers (P=0.015).

248 rs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, P2Y12 inhibitors, and the

249 ACE-inhibitors and angiotensin-receptor blockers remain excellent first lin

250 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investiga

251 (+) intake and angiotensin converting enzyme/angiotensin receptors blockers Rx.

252 Angiotensin receptor blockers should be reserved for mon

253 Although angiotensin receptor blockers should not be considered e

254 ngiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, should generally be includ

255 -blockers, angiotensin-converting inhibitors/angiotensin receptor blockers, statins, diabetic treatme

256 erting-enzyme inhibitor (lisinopril) plus an angiotensin-receptor blocker (telmisartan) or lisinopril

257 eive angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy (P<0.01).

258 from the combination of an ACE-inhibitor and angiotensin receptor blocker therapy in patients with va

259 giotensin-converting enzyme inhibitor and/or angiotensin receptor blocker therapy is the standard of

260 angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy on patients who hav

261 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 100% beta-blocker

262 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 35% beta-blocker t

263 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 51% beta-blocker t

264 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confide

265 Angiotensin-converting enzyme inhibition/angiotensin-receptor blocker therapy is well tolerated i

266 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker throughout the study.

267 Angiotensin receptor blocker treatment may blunt the har

268 nd to identify patients who can benefit from angiotensin receptor blocker treatment.

269 of associations and to explore the impact of angiotensin receptor blocker treatment.

270 us, and has less advanced disease than prior angiotensin receptor blocker trials in HCM.

271 Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker uptake increased from 46% t

272 r angiotensin-converting enzyme inhibitor or angiotensin receptor blocker usage during continuous flo

273 d angiotensin converting enzyme inhibitor or angiotensin receptor blocker usage were not significantl

274 y angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use at discharge was associ

275 .5%, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use in 24.9+/-1.9%, and asp

276 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use in patients with an Ame

277 s in angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use or anticoagulation for

278 , angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, and nonsmoking status-

279 Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, beta-blocker use, anti

280 angiotensin-converting enzyme inhibitor use, angiotensin receptor blocker use, BMI z-score for age an

281 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use-is well suited to provi

282 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers use, was similar between c

283 were randomly assigned to receive either the angiotensin receptor blocker valsartan (titrated to 320

284 rketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysi

285 RNi with neprilysin inhibitor sacubitril and angiotensin receptor blocker valsartan on myocardial rem

286 Furthermore, administration of the angiotensin receptor blocker valsartan to intact mice re

287 the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard thera

288 e-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibito

289 LCZ696, which consists of an angiotensin receptor blocker (valsartan [VAL]) and a nep

290 An angiotensin receptor blocker was administered at time 18

291 Chronic treatment with angiotensin receptor blockers was associated with better

292 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was indicated in 18.1% of

293 channel blockers (CCBs), alpha-blockers, and angiotensin receptor blockers-was significantly better t

294 Angiotensin receptor blockers were associated with lower

295 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, which together explained

296 etic subjects not treated with ACE inhibitor/angiotensin receptor blocker who had the TT-ID-AA/AC gen

297 converting enzyme inhibitors or losartan, an angiotensin receptor blocker, will decrease the rate of

298 loped by scientists at Novartis, combines an angiotensin receptor blocker with a neprilysin inhibitor

299 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP an

300 scle fibrosis and improved pain Losartan, an angiotensin-receptor blocker with anti-fibrotic abilitie

301 ensin-converting enzyme) inhibitors or ARBs (angiotensin receptor blockers) with beta-blockers (BBs)